FDA Expands Polyarticular-Course JIA Indications for Tofacitinib FDA Expands Polyarticular-Course JIA Indications for Tofacitinib

The approval of tablet and oral solution formulations, announced this week by the drug ' s manufacturer Pfizer, marks the first Janus kinase inhibitor to be approved for the condition in the US.FDA Approvals

Source: Medscape Medical News Headlines - October 1, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news